Anebulo Pharmaceuticals, Inc. financial data

Symbol
ANEB on Nasdaq
Location
Lakeway, TX
Fiscal year end
30 June
Latest financial report
10-Q - Q4 2025 - 12 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 8.1% % -23%
Return On Equity -75% % 38%
Return On Assets -69% % 36%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40,784,731 shares -0.73%
Common Stock, Shares, Outstanding 41,084,731 shares 0%
Entity Public Float $15,057,677 USD 59%
Common Stock, Value, Issued $41,086 USD 0%
Weighted Average Number of Shares Outstanding, Basic 41,084,731 shares 50%
Weighted Average Number of Shares Outstanding, Diluted 41,084,731 shares 50%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,739,275 USD -0.32%
General and Administrative Expense $5,364,101 USD 26%
Operating Income (Loss) $9,103,376 USD -14%
Nonoperating Income (Expense) $1,124,628 USD 233%
Net Income (Loss) Attributable to Parent $7,978,748 USD -4.1%
Earnings Per Share, Basic -0.18 USD/shares 36%
Earnings Per Share, Diluted -0.18 USD/shares 36%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $9,041,570 USD -40%
Assets, Current $9,273,766 USD -40%
Other Assets, Noncurrent $148,231 USD -67%
Assets $9,421,997 USD -41%
Accounts Payable, Current $554,862 USD 74%
Accrued Liabilities, Current $930,784 USD 66%
Liabilities $1,485,646 USD 69%
Retained Earnings (Accumulated Deficit) $78,046,258 USD -11%
Stockholders' Equity Attributable to Parent $7,936,351 USD -47%
Liabilities and Equity $9,421,997 USD -41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,273,076 USD 25%
Common Stock, Shares Authorized 75,000,000 shares 50%
Common Stock, Shares, Issued 41,084,731 shares 0%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,273,076 USD 25%
Deferred Tax Assets, Valuation Allowance $7,978,725 USD 25%
Deferred Tax Assets, Gross $7,978,725 USD 25%
Deferred Tax Assets, Operating Loss Carryforwards $5,149,067 USD 38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2,000,000 shares 0%
Additional Paid in Capital $85,941,523 USD 1.1%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense $234,000 USD -83%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%